Femasys Inc. (NASDAQ:FEMY) Short Interest Update

Femasys Inc. (NASDAQ:FEMY) was the target of a large drop in short interest in the month of June. As of June 15th, there was short interest totaling 198,600 shares, a drop of 94.0% from the May 31st total of 3,326,404 shares. Based on an average daily volume of 78,232 shares, the days-to-cover ratio is currently 2.5 days. Currently, 7.1% of the company’s shares are sold short.

Femasys Stock Up 5.0%

Femasys stock traded up $0.18 during mid-day trading on Friday, hitting $3.78. The company’s stock had a trading volume of 51,552 shares, compared to its average volume of 63,356. Femasys has a 52-week low of $3.50 and a 52-week high of $22.20. The company has a market cap of $11.42 million, a PE ratio of -0.70 and a beta of -2.23. The company has a debt-to-equity ratio of 0.53, a current ratio of 3.91 and a quick ratio of 1.98. The firm’s 50 day moving average is $6.73 and its 200 day moving average is $9.92.

Femasys (NASDAQ:FEMY) last released its earnings results on Friday, May 8th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($1.33) by $1.43. The company had revenue of $0.42 million for the quarter, compared to analysts’ expectations of $0.77 million. Femasys had a negative return on equity of 258.08% and a negative net margin of 521.97%.

Analysts Set New Price Targets

Several analysts have issued reports on FEMY shares. Weiss Ratings upgraded Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, June 3rd. Wall Street Zen upgraded shares of Femasys to a “hold” rating in a report on Saturday, June 13th. Finally, Lake Street Capital began coverage on shares of Femasys in a research report on Tuesday, March 3rd. They issued a “buy” rating and a $30.00 target price on the stock. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $106.67.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Kovack Advisors Inc. purchased a new stake in Femasys in the 4th quarter worth approximately $27,000. HRT Financial LP purchased a new position in shares of Femasys during the 4th quarter valued at $30,000. Cetera Investment Advisers purchased a new position in shares of Femasys during the 4th quarter valued at $36,000. Osaic Holdings Inc. acquired a new position in shares of Femasys in the second quarter worth $45,000. Finally, State Street Corp increased its stake in shares of Femasys by 43.5% in the fourth quarter. State Street Corp now owns 80,869 shares of the company’s stock worth $47,000 after acquiring an additional 24,500 shares during the last quarter. Institutional investors and hedge funds own 65.27% of the company’s stock.

About Femasys

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.